Darolutamida de Bayer más ADT y radioterapia reduce 58% el riesgo de metástasis o muerte en cáncer de próstata con alto riesgo de recaída
- Bayer anunció que darolutamida, combinada con ADT y radioterapia, reduce el riesgo de metástasis o muerte en pacientes con cáncer de próstata.
- El beneficio corresponde a pacientes con alto riesgo de recaída.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on October 24, 2026, and is solely responsible for the information contained therein.